QI
VIRX

QS Investors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

QS Investors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$495K Buy
+43,618
New +$438K 0.01% 741

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

QS Investors's VIRX Position: Q2 2021 in Review

QS Investors opened a new position in Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2021: 43,618 shares worth $495K. The stake represents 0.01% of the portfolio and ranks #741 among its holdings.

63 funds tracked by Wall St. Rank hold VIRX as of Q2 2021.

  • QS Investors held 43,618 shares of Viracta Therapeutics, Inc. Common Stock worth $495K as of Q2 2021.
  • Viracta Therapeutics, Inc. Common Stock was a new QS Investors position in Q2 2021.
  • Viracta Therapeutics, Inc. Common Stock made up 0.01% of QS Investors's portfolio in Q2 2021, its #741 holding.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.